An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure

An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure

Bibliographic Details
Main Authors:	Domingos Sousa, Maria Eduarda Couto, Alda Tavares, Teresa Ribeiro, Fabiana Santos Muñoz, Nelson Domingues, Isabel Oliveira, Mário Mariz
Format:	Article
Language:	English
Published:	Wiley 2020-11-01
Series:	eJHaem
Online Access:	https://doi.org/10.1002/jha2.123

Similar Items

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
by: Domingos Sousa, et al.
Published: (2020-11-01)

Polymicrobial lung infection associated with idelalisib administration
by: Eva Lázaro-López, et al.
Published: (2018-01-01)

Grave diarrhea associated with idelalisib administration
by: David Suárez del Olmo, et al.
Published: (2016-05-01)

Hyperleucocytosis as an unusual presentation of hypereosinophilic pneumonitis with acute respiratory distress syndrome
by: Saleh Saad Alshehri, et al.
Published: (2022-03-01)

Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia
by: Silvia Martinelli, et al.
Published: (2018-12-01)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
by: Sven Nerdinger, et al.
Published: (2019-03-01)

P626: FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL
by: S. Skånland, et al.
Published: (2022-06-01)

Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report
by: M. D’Aveni-Piney, et al.
Published: (2018-06-01)

Idelalisib may have the potential to increase radiotherapy side effects
by: Thomas Gryc, et al.
Published: (2017-06-01)

Myeloid Disease with the CSF3R T618I Mutation after CLL
by: Maria Eduarda Couto, et al.
Published: (2020-01-01)

An Unusual Cause of Organizing Pneumonia: Hydrocarbon Pneumonitis
by: Kuruswamy Thurai Prasad, et al.
Published: (2017-06-01)

An unusual cause of respiratory failure
by: Sahara N. Saltijeral, et al.
Published: (2020-09-01)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
by: Iris de Weerdt, et al.
Published: (2017-10-01)

Parasitic infestation of lung: An unusual cause of interstitial pneumonitis
by: Parth Shah, et al.
Published: (2016-01-01)

Diesel siphoner's lung: An unusual cause of hydrocarbon pneumonitis
by: Tirtha Man Shrestha, et al.
Published: (2021-01-01)

Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
by: Sven de Vos, et al.
Published: (2016-12-01)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
by: Nadine Kutsch, et al.
Published: (2022-06-01)

An unusual case of hypercapnic respiratory failure
by: Nimeh Najjar, et al.
Published: (2018-01-01)

An Unusual Case of Lorlatinib-Induced Pneumonitis: A Case Report
by: Philippa Kate Harrison, et al.
Published: (2022-03-01)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
by: Steven E. Coutre, et al.
Published: (2018-06-01)

Dabrafenib, idelalisib and nintedanib act as significant allosteric modulator for dengue NS3 protease.
by: R V Sriram Uday, et al.
Published: (2021-01-01)

An Unusual Suspect Causing Hypoxemic Respiratory Failure
by: Masooma Aqeel MD, et al.
Published: (2017-01-01)

An Unusual cause of Acute Hypercapneic Respiratory Failure
by: Janice Wang, et al.
Published: (2011-01-01)

An Unusual Cause of Acute Hypercapneic Respiratory Failure
by: Janice Wang, et al.
Published: (2011-11-01)

Acute hypoxic respiratory failure due to Lenalidomide-induced interstitial pneumonitis in a patient with multiple myeloma
by: Kyle T. O’Meara, et al.
Published: (2024-07-01)

BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
by: Lorenzo Falchi, et al.
Published: (2016-02-01)

A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
by: Joseph Gabriel Gabriel MD, et al.
Published: (2017-05-01)

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
by: Barry D Hock, et al.
Published: (2017-01-01)

Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas
by: Madanat YF, et al.
Published: (2016-03-01)

Pneumonitis Akut dan Gagal Napas Setelah Mendapatkan Injeksi Silikon Cair di Payudara [Acute Pneumonitis and Respiratory Failure after Breast Silicon Injection: A Case Report]
by: Cut Diana Laili, et al.
Published: (2015-05-01)

Unusual variant of pulmonary lesion (lymphocytic interstitial pneumonitis) in systemic lupus erythematosus
by: O V Blagova, et al.
Published: (2008-05-01)

Ponatinib-induced pneumonitis with severe acute respiratory distress syndrome
by: Sofia Dinis Ferreira, et al.
Published: (2023-11-01)

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib
by: Krause G, et al.
Published: (2018-08-01)

An unusual but unmissable link between summer-type hypersensitivity pneumonitis and asthma in an old house
by: Naoya Yasokawa, et al.
Published: (2020-01-01)

Retraction Note: Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma
by: Dan Yue, et al.
Published: (2024-10-01)

Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report
by: Salma Machan, et al.
Published: (2020-02-01)

Good Profile of Efficacy/Tolerance of Bortezomib or Idelalisib in Waldenström Macroglobulinemia Associated with Acquired Von Willebrand Syndrome
by: Ojeda-Uribe M, et al.
Published: (2020-02-01)

Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis
by: Daphne W. Dumoulin, et al.
Published: (2020-10-01)

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
by: Eyre, T, et al.
Published: (2017)

Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia
by: Martin F.M. de Rooij, et al.
Published: (2016-03-01)